Baiyong LI,Yu XIA,Zhongmin WANG,Peng ZHANG,Xinghua PANG
申请号：
US16562236
公开号：
US20200206346A1
申请日:
2019.09.05
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
